James F. Cummings, MD

Chief Medical Officer
VAXART
South San Francisco, California, United States

Disclosure(s): VAXART: Stocks/Bonds (Public Company)

Presentation(s):

• 220 - A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted Norovirus Vaccine VXA-G1.1-NN is Immunogenic, Efficacious, and Reduces Viral Shedding Following Norovirus Challenge

  Thursday, October 17, 2024
  3:45 PM – 4:00 PM US PT

• 594 - A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Orally Administered Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females ≥ 18 years Old and Their Breast-feeding Infants

  Saturday, October 19, 2024
  2:15 PM – 2:30 PM US PT